Published in Vaccine Weekly, January 9th, 2002
Under the contract, after NIAID approves a vaccine candidate it will issue a task order to fund Protein Sciences to develop and manufacture clinical materials suitable for Phase I, II and III human clinical trials. Industry and institutions in the U.S. or abroad qualify for funding.
"Our company has a long history of involvement in developing HIV/AIDS vaccines, and we have extensive experience...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly